Nancy Hudecek, RN, BSN, MS, has joined AirStrip Technologies^TM as the Vice President of Clinical Excellence and Risk Management, AirStrip officials announced today.

Brookfield Asset Management Inc. (TSX: BAM.A)(NYSE: BAM)(EURONEXT: BAMA) is pleased to announce that Jeff Kendrew has joined the firm as Chief Development Officer of its global infrastructure platform. Prior to his appointment, Mr. Kendrew served as Managing Director and Chief Executive Officer of Prime Infrastructure (ASX: PIH), which he oversaw during Brookfield's sponsorship of its recapitalization and restructuring in November 2009.

Veda Walcott has been named vice president of quality and corporate compliance officer of Cook Pharmica, the global biopharmaceutical contract development and manufacturing division of Cook Medical. She has been an employee of Cook Pharmica since 2005, and in her new role will be responsible for leading Cook Pharmica’s quality and compliance programs and will oversee regulatory and validation support activities.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) today announced the appointment of Thomas J. Knapp as Senior Vice President, General Counsel and Corporate Secretary, a newly-created position, effective February 19, 2010, reporting to James J. Egan, Chief Operating Officer of Sucampo Pharmaceuticals, Inc. Mr. Knapp will be responsible for all in-house and outside legal activities for Sucampo, including governance and compliance activities, contract administration and records retention.

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Andreas Rummelt, Ph.D., has been appointed a Director of Alexion, effective immediately.

Immunovaccine Inc. (TSX VENTURE: IMV) announced today that James W. Hall, C.A. has been appointed to its Board of Directors. With over 25 years of financial and investment experience in Canada and the U.S., Mr. Hall will serve as chair of Immunovaccine's audit committee.

Malvern, UK: Malvern Instruments has expanded its team serving the particle characterization market in China with the appointment of Terry Liu to the role of Process Specialist. Terry is part of the Malvern China team and works from the company’s Shanghai office.

A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced the appointment of Stephen Davis to its board of directors. Mr. Davis was the chief executive officer for Neurogen Corporation, which was recently acquired by Ligand Pharmaceuticals. His appointment brings the number of A.P. Pharma board members to seven.

Medpace, Inc. today announced the addition of Samer E. Kaba, MD, as a Medical Director with therapeutic expertise in guiding global clinical trials in the area of Neuroscience. Dr. Kaba brings a wealth of clinical development expertise in the areas of neurology, psychiatry, and analgesia.